We are nearing the close of another round of successful investment in the o2h human health Funds. The table below shows investments that you could be investing into over the coming months. The final date to receive cleared funds is the 5th April 2023 for the Knowledge-intensive Human Health EIS fund.
Below is the selection of opportunities –
Biotech – Services
Metrion is a specialist ion channel contract research organisation (CRO), based in Granta Park, Cambridge, UK. The Company provides a wide range of ion channel assay services to the worldwide pharmaceutical and bioscience industry. Ion channels are a major target for new drug discovery and also important in safety assessment. Metrion is a leader in its field and generated revenues of £5.3m in 2022, a 56% increase on 2021, while also reporting positive EBITDA. Metrion is seeking growth capital to expand its laboratory capacity, provide regulated (GLP) cardiac safety services and expand its business development capabilities in the USA. o2h Ventures has pre-emption rights to ensure deal access.
Biotech – Lung
A Spin-out from the University of Nottingham now based in Cambridge, UK, was Seeded by o2h Ventures and Nottingham University. The company has a platform of over 500 compounds targeted against various integrins, with the most advanced molecules being progressed as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF). This is a life-limiting condition, approximately 3 to 5 years from diagnosis, in which the lungs become scarred and breathing becomes increasingly difficult resulting in a very poor quality of life for patients. 1The Global Idiopathic Pulmonary Fibrosis Market is set to reach $10.1 Billion by 2029. Alevin recently won the prestigious industry award for Best Biotech Startup award for best start-up of the year from the OBN. o2h Ventures has pre-emption rights to ensure deal access.
Biotech – Ocular
A spin-out from the University of Nottingham and now based in Cambridge, UK aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies. The company has successfully completed its Phase I in Australia study and will now seek further investment to conduct a Phase II clinical trial in the USA. o2h Ventures has pre-emption rights to ensure deal access.
Biotech – Nanoparticle
A spinout of University College London (UCL) and now based at the Babraham Research Campus, Cambridge, UK is developing its patented targeted nanoparticle technology, PolyNaut® for use in a therapeutic setting to allow genetic materials to cross the blood brain barrier and other biological barriers. The business model is to exploit the polyNaut platform through the development of an internal pipeline focusing on rare, genetically driven diseases and early collaboration with pharmaceutical companies. Licences with significant upfronts, milestones, and royalties are expected from both platform and products. The company has several on-going collaborations with pharma and biotech, of which 5 are in the top 20 pharma. o2h Ventures has pre-emption rights to ensure deal access.
A company that utilises Machine Learning to predict experimental outcomes with their Simulated Cell™ platform. These simulations can decrease the timelines of drug discovery and development and boost the chances of clinical success. Turbine has 2 current collaborations with big pharma. Turbine recently raised Euro20M from Mercia and Mercks Venture fund and o2h Ventures will seek to use its pre-emption rights to join this investment round.